Original Articles

Oxybutynin and Tolterodine in a Trial for Treatment of Overactive Bladder in Iranian Women

Abstract

Objective: To evaluate the efficacy and side effects of Oxybutinin in comparison to tolterodine in treatment of overactive bladder (OAB) with detrussor overactivity (DOA) in Iranian women.
Materials and methods: One hundred Iranian old women with clinical symptoms of OAB who show IDO in the filling cystometry participated in this randomized double-blinded parallel-group by using two kinds of the drugs for 4- week course (2 mg tolterodine twice-daily, or oxybutinin 5 mg, three times a day) in alike packages. We collected data from 3-day FVC before and after the treatment course. The effectiveness of each drug was studied using the paired t-test and improvement after treatment between two groups was compared by independent T-test.
Results: Positive changes in urinary urgency, Frequency and Urge incontinence after treatment in both groups were seen but mean improvements in the all were larger in the patients who treated by oxybutinin especially in terms of urgency and Urge incontinence. Dry mouth was the most common side-effect in two groups. Unlike other studies it was higher in the tolterodine group but the difference was not significant.
Conclusion: Four week treatment with oxybutinin was better than tolterodine in improving urgency and urge incontinence but there were not statistically significance between them.

Herbison P, Hay-Smith J, Ellis G, Moore K.Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003; 326:841-4.

Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004; 3:46-53.

Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs 2004; 64:1643-56.

Diokno A, Sand P, Labasky R, Sieber P, Antoci J,Leach G, et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. Int Urol Nephrol 2002; 34:43-9.

Kreder K, Mayne C, Jonas U. Long-term safety,tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder.Eur Urol 2002; 41:588-95.

Appell RA, Abrams P, Drutz HP, Van Kerrebroeck PE,Millard R, Wein A. Treatment of overactive bladder:long-term tolerability and efficacy of tolterodine.World J Urol 2001; 19:141-7.

Lawrence M, Guay DR, Benson SR, Anderson MJ.Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis.Pharmacotherapy 2000; 20:470-5.

Diokno AC, Appell RA, Sand PK, Dmochowski RR,Gburek BM, Klimberg IW, et al. OPERA Study Group.Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overtive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78:687-95.

Geoffrion R. Treatments for overactive bladder: focus on pharmacotherapy. J Obstet Gynaecol Can. 2012;34:1092-101.

Van Kerrebroeck P, Kreder K, Jonas U, Zinner N,Wein A, Tolterodine Study Group. Tolterodine oncedaily:superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57:414-21.

Abrams P, Malone-Lee J, Jacquetin B, Wyndaele JJ,Tammela T, Jonas U, et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001; 18:551-60.

Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2005; 20.

Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6.

Radley SC, Rosario DJ, Chapple CR, Farkas AG. Conventional and ambulatory urodynamic findings in women with symptoms suggestive of bladder overactivity. J Urol 2001; 166:2253-8.

Files
IssueVol 8, No 2 (June 2014) QRcode
SectionOriginal Articles
Keywords
Frequency Volume Chart Over Active Bladder Oxybutynin Tolterodine Urodynamic Study

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Aziminekoo E, Ghanbari Z, Hashemi S, Nemati M, Haghollahi F, Shokuhi N. Oxybutynin and Tolterodine in a Trial for Treatment of Overactive Bladder in Iranian Women. J Family Reprod Health. 2014;8(2):73-6.